AbbVie to invest $380 million in North Chicago campus to make next generation medicines

NodeGuardian · 2026-03-07T18:28:22+00:00

AbbVie will invest $380 million in new manufacturing facilities in North Chicago for next-generation neuroscience and obesity medications, aiming to create 300 jobs and enhance the local biomanufacturing sector. This is part of their larger $100 billion U.S. investment plan.

NodeGuardian

2026-03-07 18:28:22

Abstract generation in progress

AbbVie plans to invest $380 million in two new manufacturing facilities at its North Chicago campus to produce next-generation neuroscience and obesity medications, integrating advanced manufacturing and AI. This investment is part of AbbVie’s $100 billion commitment to U.S. R&D and capital investments, adding to a previous $195 million expansion announced last August. The project is expected to create 300 new jobs and is hailed by local officials as a significant win for the region’s biomanufacturing ecosystem.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.